ArticleThe Journal of clinical endocrinology and metabolism2024
Lower Prevalence of Diabetic Ketoacidosis at Diagnosis in Research Participants Monitored for Hyperglycemia.
Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 6 citations in OpenAlex.
- Increasing Trends in Hospitalisation With Diabetic Ketoacidosis at Type 1 Diabetes Diagnosis Among Children and Youth in the United States and England, 2002-2020.Diabetes, obesity & metabolism · 2026Article
- International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process.Diabetologia · 2026Article
- Identifying diabetic ketoacidosis encounters at diagnosis among children with type 1 diabetes in claims data.Journal of the Endocrine Society · 2026Article
- Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.Journal of clinical medicine · 2026Review
- Screening and Monitoring for Presymptomatic Type 1 Diabetes: A Time for Action.Hormone research in paediatrics · 2026Review
- Bringing early detection to life: real-world operationalization of a presymptomatic type 1 diabetes screening and monitoring pilot program.BMJ open diabetes research & care · 2026Article
- An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.Diabetes, obesity & metabolism · 2026Review
- Extending the Eisenbarth Model: Stage 0 as a Provisional Framework for Early Risk Stratification and Prevention in Type 1 Diabetes.Journal of diabetes research · 2026Review
- Health economic considerations of screening for early type 1 diabetes.Diabetes, obesity & metabolism · 2025Review
- Unlocking the dual healing powers of plant-based metallic nanoparticles: managing diabetes and tackling male infertility challenges.Frontiers in endocrinology · 2025Review
- Insights into Knowledge and Attitudes About Autoantibody Screening from People Affected by Type 1 Diabetes: A Brief Report.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
contextIn Colorado children, the prevalence of diabetic ketoacidosis (DKA) at diagnosis of type 1 diabetes has been increasing over time.
objectiveTo evaluate the prevalence of and factors involved in DKA at type 1 diabetes diagnosis among participants followed in monitoring research studies before diagnosis compared to patients from the community.
methodsWe studied patients < 18 years diagnosed with type 1 diabetes between 2005 and 2021 at the Barbara Davis Center for Diabetes and compared the prevalence of and factors associated with DKA at diagnosis among participants in preclinical monitoring studies vs those diagnosed in the community.
resultsOf 5049 subjects, 164 were active study participants, 42 inactive study participants, and 4843 were community patients. Active study participants, compared to community patients, had lower HbA1c (7.3% vs 11.9%; P < .001) and less frequently experienced DKA (4.9% vs 48.5%; P < .001), including severe DKA (1.2% vs 16.2%; P < .001). Inactive study participants had intermediate levels for both prevalence and severity of DKA. DKA prevalence increased in community patients, from 44.0% to 55%, with less evidence for a temporal trend in study participants. DKA prevalence was highest in children < 2 years (13% in active study participants vs 83% in community patients). In community patients, younger age (P = .0038), public insurance (P < .0001), rural residence (P < .0076), higher HbA1c (P < .0001), and ethnicity minority status (P < .0001) were associated with DKA at diagnosis.
conclusionWhile DKA prevalence increases in community patients over time, it stayed < 5% in active research participants, who have a 10 times lower prevalence of DKA at diagnosis, including among minorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.